

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/345,373	07/01/1999	STEVEN M. RUBEN	1488.036000A	1167
7590 10/09/2003 STERNE KESSLER GOLDSTEIN & FOX PLLC 1100 NEW YORK AVENUE NW SUITE 600 WASHINGTON, DC 200053934			EXAMINER	
			SAOUD, CHRISTINE J	
			ART UNIT	PAPER NUMBER
			1647	$\Omega_{\ell}$
			DATE MAILED: 10/09/2003	$\alpha$

Please find below and/or attached an Office communication concerning this application or proceeding.



# Office Action Summary

Application No.

Applicant(s)

09/345,373

RUBEN et al.

Examiner

**Christine Saoud** 

Art Unit \_ 1647



	· · · · · · · · · · · · · · · · · · ·	
	The MAILING DATE of this communication appears	
	or Reply	
THE N - Extens mailing - If the p - If NO p - Failure - Any re	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION. ions of time may be available under the provisions of 37 CFR 1.136 (a). In red date of this communication. eriod for reply specified above is less than thirty (30) days, a reply within the eriod for reply is specified above, the maximum statutory period will apply at to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	no event, however, may a reply be timely filed after SIX (6) MONTHS from the estatutory minimum of thirty (30) days will be considered timely.  Ind will expire SIX (6) MONTHS from the mailing date of this communication.  Examplication to become ABANDONED (35 U.S.C. § 133).
Status	patent term adjustment. See 57 CFT 1.754(b).	
1) 💢	Responsive to communication(s) filed on Jul 2, 200	3
2a) 💢	This action is <b>FINAL</b> 2b) □ This action	on is non-final.
3) 🗆	Since this application is in condition for allowance e closed in accordance with the practice under Ex par	xcept for formal matters, prosecution as to the merits is te Quayle, 1935 C.D. 11; 453 O.G. 213.
Disposi	tion of Claims	
4) 🗶	Claim(s) <u>183-200</u>	is/are pending in the application.
4	a) Of the above, claim(s)	is/are withdrawn from consideration.
5) 🗆	Claim(s)	is/are allowed.
6) 💢	Claim(s) <u>183-200</u>	is/are rejected.
7) 🗆	Claim(s)	is/are objected to.
8) 🗆		are subject to restriction and/or election requirement.
Applica	tion Papers	
9) 🗆	The specification is objected to by the Examiner.	
10)	The drawing(s) filed on is/are	a) $\square$ accepted or b) $\square$ objected to by the Examiner.
	Applicant may not request that any objection to the d	
11)	The proposed drawing correction filed on	is: a) $\square$ approved b) $\square$ disapproved by the Examiner.
	If approved, corrected drawings are required in reply t	o this Office action.
12)	The oath or declaration is objected to by the Exami	ner.
•	under 35 U.S.C. §§ 119 and 120	
_	Acknowledgement is made of a claim for foreign pr	iority under 35 U.S.C. § 119(a)-(d) or (f).
	☐ All b)☐ Some* c)☐ None of:	
	1. Certified copies of the priority documents hav	
	<ol> <li>Certified copies of the priority documents hav</li> <li>Copies of the certified copies of the priority defined.</li> </ol>	e been received in Application No
	application from the International Burea ee the attached detailed Office action for a list of the	au (PCT Rule 17.2(a)).
14)	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. § 119(e).
<b>a</b> ) [	The translation of the foreign language provisiona	l application has been received.
15)	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. §§ 120 and/or 121.
Attachm		□
	otice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).
	otice of Draftsperson's Patent Drawing Review (PTO-948)  formation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal Patent Application (PTO-152)  8) Other:
at IXI iu	Offination Disclosure Statement(s) (F10-1445) Paper NO(s).	or outer.

Art Unit: 1647

2

### **DETAILED ACTION**

### Response to Amendment

- 1. Claims 183, 189 and 195 have been amended as requested in the amendment of paper #25, filed 02 July 2003. Claims 183-200 are pending in the instant application.
- 2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 3. Any objection or rejection of record which is not expressly repeated in this action has been overcome by Applicant's response and withdrawn.
- 4. Applicant's arguments filed 02 July 2003 have been fully considered but they are not deemed to be persuasive.

## Claim Rejections - 35 USC § 112

- 5. The following is a quotation of the first paragraph of 35 U.S.C. 112:
  - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 6. Claims 183-200 stand rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one

Art Unit: 1647

skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention for the reasons of record in paper #22. This is a new matter rejection.

Applicant asserts at page 6 of the response that the specification contemplates polypeptides with percent identity in conjunction with deletion mutants. Applicant points to page 36, lines 10-16 for support of this conclusion. However, a reading of this section of the specification does not support the current claims to a particular deletion mutant (i.e. Ser69-Ser208) with a percent identity. The disclosure at page 36 of the specification does not contemplate percent identity with any particular fragment of KGF2, and therefore, this inventive concept does not find support in the instant specification as originally filed.

Applicant asserts that page 66, line 29 to page 67 line 1 links deletion mutants that can be bound by an antibody that specifically binds SEQ ID NO:2. However, the specification at pages 66-67 is directed to generation of antibodies, not proteins which have a specific activity. The invention which is being claimed is a mutant protein which has a particular activity of being bound by a specific antibody. The specification fails to contemplate a mutant protein which has the function of being bound by an antibody that binds to the protein of SEQ ID NO:2, absent evidence to the contrary. The instant specification contemplates antigenic portions (see pages 32 and 37-41), but not the broader invention of polypeptides which contain mutations and which bind antibodies that specifically bind a polypeptide of SEQ ID NO:2. While percent identity would encompass small truncations and therefore, contiguous portions of SEQ ID NO:2, the recitation of percent identity also encompasses point mutations, deletions and insertions, wherein this concept does not find support in the instant specification as filed.

Art Unit: 1647

#### Conclusion

- 7. Claims to an isolated polypeptide comprising an amino acid sequence identical to Ser (69)
- Ser (208) of SEQ ID NO:2 are free of the prior art of record.

#### **Conclusion**

8. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christine Saoud, Ph.D., whose telephone number is (703) 305-7519. The examiner can normally be reached on Monday to Thursday from 8AM to 2PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, can be reached on (703) 308-4623.

Certain papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1 (CM1). The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by Applicant or Applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers.

Art Unit: 1647

Page 5

Official papers filed by fax should be directed to (703) 308-4556. If this number is out of service, please call the Group receptionist for an alternate number. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294. Official papers should NOT be faxed to 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

CHRISTINE J. SAOUD
PRIMARY EXAMINER
Christine J. Saend

.